Dr. Sazaly has been involved with dengue research for over 20 years and has also maintained strong research interest in emerging infectious diseases. His interest in dengue, in particular, is rooted in its knowledge gaps: “it is a fascinating disease needing a lot more research to take on.” In an interview with DVI, Dr. Sazaly shares more on his views of dengue prevention and control and needs in the dengue research field.

Every three months, the Dengue Vaccine Initiative (DVI) highlights a “Dengue Champion,” calling attention to that person’s contribution to the dengue vaccine research field and their commitment to the fight against dengue fever. Dr.

Dr. Capeding led the first Phase 3 trial ever completed for a dengue vaccine candidate.

Titled, “New chapter unfolding in the fight against dengue with an unwritten ending,” the Dengue Vaccine Initiative’s (DVI) editorial just published in the October issue of Transactions

With the slogan “Immunization for a healthy future. Know, Check, Protect” WHO reminds us this week that vaccines prevent 2-3 million deaths each year. Just imagine this: 2 to 3 million lives. This equals the populations of countries like Mongolia or Botswana.  

Sabin is happy to announce the arrival of our 2012 Annual Report, featuring highlights from our three programs – Vaccine Advocacy and Education, The Sabin Product Development Partnership, and the Global Network for Neglected Tropical Diseases.
For many people throughout the world, the bite of a mosquito is nothing more than a common annoyance. But for individuals living in dengue endemic countries such an annoyance can quickly turn into a life threatening condition.

Pages